Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib versus chemotherapy or pembrolizumab in FGFR-altered advanced urothelial cancer
MOH_2020-12-10_009565Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erdafitinib in transitional cell carcinoma (TCC) and bladder cancer (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall survival. Started May 2018; status: completed.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on MOH_2020-12-10_009565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-10_009565.